Biocon-Serum Combine Forces, mRNA Opportunities On Radar
Investments In Vaccine Supply Chain Likely
Serum to hold 15% in Biocon arm Biocon Biologics as part of a broad alliance that expects to leverage the partners' strengths and resources in vaccines and biologics. Pursuing opportunities based on the hot mRNA technology platform appears firmly on the table.
